Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jon Alberdi [https://www.linkedin.com/in/jonalberdi/], CEO at VIVEbiotech. [https://vivebiotech.com/en/] Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jon, covering: * Falling in love with the world of management and its role in influencing people and society * Why, after 12 years in the B2B automotive sector, did he decide to jump into the life science space? * His first impressions of the sector and the viral vector space, and why he saw nothing but potential to industrialize * The before and after of a PE deal with Ampersand [https://ampersandcapital.com/] - speed, challenge, and intensity * Riding the growth of CAR-T products, and which therapy areas are driving demand Graduating in Economics from the University of the Basque Country - Sarriko, Bilbao, he received complementary education in management and leadership. His professional career is closely tied to the Financial Function of several companies operating in diverse sectors, including investment banking, sports service management, and the automotive and aftermarket industries. In 2008, he joined the global industrial public company GKN [https://www.gknaerospace.com/], where he held several financial controlling roles, including the R&D department at the worldwide product development centre. He later moved to Germany to take on the responsibility of Financial Direction for a global business unit of GKN, where he stayed for five years until he joined VIVEbiotech, gaining a solid background in management within an international environment. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing [https://www.ramarketingpr.com/], an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Philip Lee [https://www.linkedin.com/in/philiplee2], CEO at GeneFab [https://www.genefab.com/]. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Philip, covering: * The role of luck in the development of his entrepreneurial journey of multiple biopharma start-ups * Bootstrapping a biological tech company and then selling to Millipore, along with lessons learnt from a more prominent global organization * Building a new company from the back of a napkin to an IPO on the NASDAQ [https://www.nasdaq.com/] * Creating a technology platform and operational capability with real therapeutic application that led to the spin-out of Genefab * Bridging the gap for early-stage cell therapy companies with aligned incentives and a non-transactional model Philip Lee is a bioengineer, biotechnology entrepreneur, and executive who has spent the last 20 years building companies and commercializing products, including cell and gene therapies, synthetic biology platforms, scientific instrumentation, cell culture systems, and advanced manufacturing services. He has been the “first employee” at multiple ventures with leadership experience across diverse growth trajectories, including bootstrapping, VC and PE funding rounds, IPO, acquisition, and internal innovation within a large enterprise. Philip holds degrees from the Massachusetts Institute of Technology [https://web.mit.edu/] and the UC Berkeley [https://www.berkeley.edu/]/UCSF [https://www.ucsf.edu/] Joint Graduate Program in Bioengineering. Philip is currently the founding CEO of GeneFab, a contract research, development, and manufacturing organization focused on supporting its clients in bringing innovative genetic medicines to needy patients.  Before GeneFab, Philip was the Co-Founder and CTO of Senti Biosciences [https://www.sentibio.com/], a cell and gene therapy company applying gene circuit technology to improve the efficacy and safety of cancer cell therapies. Philip was also the co-founder and CEO of Cellasic Corp [https://www.merckmillipore.com/GB/en/life-science-research/cell-culture-systems/cellASIC-live-cell-analysis/d1Cb.qB.w58AAAE_0j13.MnA,nav], a microfluidics instrumentation company that MilliporeSigma [https://www.sigmaaldrich.com/GB/en?srsltid=AfmBOorn4ShwTR-kQBEr4EYkrh8aSXVuBNxrUsgpGD6531KnOn5zVzg8] had acquired. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing [https://www.ramarketingpr.com/], an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jodi Cook PhD [https://www.linkedin.com/in/jodicook/], President and CEO at Skylark Bio [https://skylarkbio.com/]. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jodi, covering: * How a curiosity for unanswered questions led her to a PhD and a career in biotech… and, ultimately, the magical, rare experience of getting a product to market * The full-circle moment that took Jodi from being an audiologist to becoming the preclinical biotech CEO of a gene therapy company focused on curing pediatric deafness * The reality of running a biotech company in the most challenging climate in a long time - and why she treats every dollar in the business as if it were her own * Dress to impress - no-nonsense advice on crafting the impression you want to leave on your audience * Why does she allow herself to dream of what Skylark can achieve as a business and the profound impact of gene therapies on patients? Jodi is an operationally focused business leader with experience across public and private biotechnology and medical device organizations. She brings a unique combination of scientific, clinical development, operational, and commercialization expertise to Skylark. Before leading Skylark, Dr. Cook was Senior Vice President of Gene Therapy Strategy at PTC Therapeutics [https://www.ptcbio.com/]. Before that, she served as the founding Chief Operating Officer of Agilis Biotherapeutics [https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-acquire-agilis-biotherapeutics], overseeing its $1 billion acquisition. She earned her Ph.D. from Arizona State University [https://www.asu.edu/], a Master’s in Audiology from the University of South Carolina [https://sc.edu/], and a Bachelor of Arts from Loyola University Maryland [https://www.loyola.edu/]. She completed a fellowship at Johns Hopkins Medical School in Baltimore, Maryland. She is a Board Member of Fennec Pharmaceuticals [https://fennecpharma.com/] and was previously Board Chair of STRM.BIO [https://strm.bio/]. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing [https://www.ramarketingpr.com/], an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Julien Laizé [https://www.linkedin.com/in/julien-laiz%C3%A9-1001bb116/], Director External Manufacturing CTM at Valneva [https://valneva.com/]. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Julien, covering: * Comparative views of being externally outsourced in large pharma's R&D vs a more action-oriented, small-med pharma company * Taking us behind the scenes into in-housing vs outsourcing manufacturing decisions and CDMO identification... * Why the selection process is becoming more and more challenging for buyers * The importance of reputation and track record for CDMOs, and the value of being known as a specialist * How do geopolitical issues and macro uncertainty play into the planning of external manufacturing?   Julien Laizé is a French/Italian executive with extensive and international experience in the vaccines and biologics industry. A Doctor of Pharmacy, Julien spent time at Siemens Healthineers [https://www.siemens-healthineers.com/], Novo Nordisk [https://www.novonordisk.com/] and Eli Lilly [https://www.lilly.com/uk/] before joining Valneva, a specialty vaccine company focused on developing and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing [https://www.ramarketingpr.com/], an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jason C. Foster [https://www.linkedin.com/in/jasoncfoster/], Chief Executive Officer and Executive Director at Ori Biotech [https://oribiotech.com/]. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jason, covering: * How being frustrated by big company life led to the development of a business unit within Reckitt Benckiser [https://www.reckitt.com/] that went on to be valued at $1bn * The story of how a spin-out went on to list on the LSE [https://www.lse.ac.uk/] with a cool $3.5bn market cap * Taking his skills and experience before making 18+ healthcare start-up investments,... determined to add value beyond the cash * Being wowed by the potential of CGTs and building the business he always wanted to work for in Ori The mission is to build enabling technology for power cell therapy companies and cut down the manufacturing costs by at least 50% to improve accessibility and affordability. Jason has held leading roles in consulting, healthcare and technology companies for over 20 years in the US, UK and Europe. He is CEO and Executive Director for Ori Biotech, a cell and gene therapy manufacturing technology start-up with offices in London and New Jersey. He raised a $100M Series B funding round in December 2022. Jason also serves as a Non-Executive Director of London-based health tech start-ups gripAble [https://gripable.co/] and Credentially [https://www.credentially.io/] and Auxita Pty [https://auxita.com/], an Australian healthcare data platform. As the Managing Director of Health Equity Consulting [https://www.healthequityconsult.com/], he has advised PE/VC funds, family offices, accelerators and healthTech start-ups.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing [https://www.ramarketingpr.com/], an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.